The Safety and Dose-range Study of Metacavir Enteric-coated Capsules in Patients With Chronic Hepatitis B

Inclusion Criteria: * Are at least 18 years of age and no older than 65; * Subjects,with an established clinical history of HBV at Screening,has a positive HBsAg test(\>6months) regardless of a positive/negative HBeAg test; * At Screening,HBV-DNA\>10\^5 copies/ml in HBeAg positive or HBV-DNA\>10\^4 copies/ml in HBeAg negative(HBV-DNA was evaluated by polymerase chain reaction fluorescent labeling.); * Subjects with abnormal liver function test defined as alanine aminotransferase(ALT) was 2\~10 times upper limit of normal in HBeAg positive or 1.5\~10 times upper limit of normal in HBeAg negative; * Subjects who are willing to require any other treatment for anti-hepatitis B during the study period; * Subjects who are willing to take measures for effective non-pharmaceutical contraception; * Given their signed written informed consent to participate; Exclusion Criteria: * Subjects with hepatitis C(HCV),hepatitis D(HDV),autoimmune hepatitis,hereditary liver disease or any other active hepatitis; * A positive human immunodeficiency virus(HIV) test result; * Subjects,who in the opinion of the investigator,have a current diagnosis of hepatocellular carcinoma or serum α-fetoprotein(AFP)\>100ug/L; * Subjects with severe hepatitis or decompensated liver disease defined as hepatic encephalopathy,ascites,low protein blood syndrome(albumin ≤30g/l) or variceal bleeding; * Serum Creatinine(SCr) exceeds upper limit of normal; * At Screening,ALT\>10 times upper limit of normal,Total Bilirubin(TBIL)\>double upper limit of normal or transient hepatic decompensation caused by condition aggravation; * Subjects who required treatment with nucleoside antiviral drugs such as lamivudine,Adefovir dipivoxil,Telbivudine,Tenofovir disoproxil or Entecavir before Screening; * Subjects who require treatment with interferon-α，thymosin α-1 or other antiviral therapy,immunosuppressive agents,immune modulators within 6 months before Screening; * Subjects with cardiac disease,hematological system disease,cancer,impaired immunity or psychiatric disease; * Hemoglobin\<10g/dl,white blood cell count\<3.5 10\^9/L,platelets\<80 10\^9/L; * Subjects,who in the opinion of the investigator,have a current diagnosis of pancreatitis pre-dose within 24 weeks; * History of hypersensitivity or allergy to any of the study drugs; * Subjects who participate in other clinical trials within 3 months prior to Screening; * Women who are pregnant or lactating or planning a pregnancy recently; * Subjects in the opinion of the investigator,could not participate in the study.